Vriessluijs, T.E.M.S. de

patient vaccination anti-hb hepatitis study anti-hbs titer follow-up response titer therapy hbv dna virus hiv rna load analysis level 5 years antiretroviral therapy hiv-infected baseline infection vaccine treatment hepatocellular carcinoma virologic response immunode ficiency virus hepatitis b vaccination virologic count ef ficacy hiv-infected patients resistance hbv vaccination follow-up period haart hepatitis b tenofovir signi antiretroviral –75th percentile virologic breakthrough tenofovir disoproxil fumarate hepatitis b virus mutation subject carcinoma interquartile range multivariate analysis follow-up evaluation hepatocellular liver period schedule disease hbeag serum result month revaccination signi ficantly ficiency haart use tdf therapy cohort creatinine ficacy department hepatitis b vaccine anti-hbs level <0.0001 regimen multivariate immunode hbv infection anti-hbv breakthrough hbsag durability disoproxil adefovir dipivoxil adefovir